Balversa (Erdafitinib) Approved for Advanced Bladder Cancer

MONDAY, April 15, 2019 — Balversa (erdafitinib) has been approved by the U.S. Food and Drug Administration to treat adults with advanced or spreading bladder cancer caused by a genetic defect called FGFR3 or FGFR2, the agency said in a news…
Source: Topamax